There are still a few days left to wish a very Happy New Year 2024 to our community, our investors, our readers and all those who make the Op2Lysis program live, progress and bring new hope to hemorrhagic stroke patients every day 🧓🧠🩸. We are therefore delighted to share with you the progress made in […]
Op2Lysis has been nominated for the Prix GALIEN USA 2023, in the Best StartUp category. The Prix Galien recognises outstanding achievements in improving human health and well-being around the world through the development of drugs, medical devices and other innovative approaches to better manage disease. The press release is available below:
The World Intracranial Hemorrhage Conference (WICH) meets every two years and brings together neurologists, neurosurgeons, researchers and clinicians from all fields, healthcare providers, students and community members from around the world to provide a unique opportunity to exchange ideas and share research and clinical innovations in the field of intracranial haemorrhage. The WICH 2023 conference […]
Op2Lysis was awarded a Deeptech Development Grant (ADD) to manufacture the clinical batch of OptPA, the active substance in O2L-001, for phase 1/2 in patients suffering from cerebral haemorrhage. The press release:
The European Innovation Council and SME Executive Agency (EISMA) has validated the EIC Accelerator grant contract and followed the initial recommandation of the independent jury by awarding us the maximum support, i.e. a grant of €2.5M to industrialise O2L-001. The press release: